Three patients received implants for intraocular melanoma, which were performed with the support of Mark J. Rivard, Ph.D, Associate Professor of Radiation Oncology at Tufts University School of Medicine and Chief Medical Physicist at Tufts - New England Medical Center.
"Cesium-131's unique characteristics, including minimizing healthy tissue dose, which is a benefit for the patient, may offer significant clinical advantages," said Rivard, who is also a consultant to IsoRay.
commented, "Cesium-131's higher photon energies provide improved dose homogeneity, and allows the delivery of the required dose while potentially reducing unnecessary dose to surrounding tissue."
explained that intraocular melanoma tends be most common in individuals over 40 years of age and is most commonly detected in routine eye exams where the pupils are dilated.
In other cases, symptoms may include a dark spot on the iris or blurred vision.
The course of therapy is dictated by the size of the lesion, and whether the cancer has spread throughout the eye or beyond.
"Brachytherapy has been most effective for small to medium sized tumors," added Rivard